← Back to Clinical Trials
Recruiting NCT07655323

NCT07655323 RISS Versus ESP Block in Laparoscopic Cholecystectomy

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07655323
Status Recruiting
Phase
Sponsor Ferit Yetik
Condition Postoperative Pain
Study Type INTERVENTIONAL
Enrollment 80 participants
Start Date 2026-06-18
Primary Completion 2026-12

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 75 Years
Study Type INTERVENTIONAL
Interventions
Erector Spinae Plane BlockRhomboid Intercostal-Subserratus Plane Block

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 80 participants in total. It began in 2026-06-18 with a primary completion date of 2026-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This prospective randomized controlled trial aims to compare the analgesic efficacy and effects on diaphragmatic function of bilateral erector spinae plane (ESP) block and bilateral rhomboid intercostal-subserratus plane (RISS) block in patients undergoing elective laparoscopic cholecystectomy. Postoperative pain scores, opioid consumption, diaphragmatic excursion, pulmonary function, and recovery outcomes will be evaluated.

Eligibility Criteria

Inclusion Criteria:- * Age between 18 and 75 years * ASA physical status I-III * Scheduled for elective laparoscopic cholecystectomy under general anesthesia * Provision of written informed consent Exclusion Criteria: * Coagulation disorders or anticoagulant therapy * Known allergy to local anesthetics * Infection at the block application site * Pregnancy or lactation * Chronic opioid use * Cognitive impairment * Refusal to participate in the study * Technical inability to perform the block * Failed block

Contact & Investigator

Central Contact

Mürsel Ekinci, MD

✉ drmurselekinci@gmail.com

📞 +905067137596

Principal Investigator

Mürsel Ekinci, MD

PRINCIPAL INVESTIGATOR

Bursa City Hospital, Health Sciences University Bursa Faculty of Medicine

Frequently Asked Questions

Who can join the NCT07655323 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Postoperative Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07655323 currently recruiting?

Yes, NCT07655323 is actively recruiting participants. Contact the research team at drmurselekinci@gmail.com for enrollment information.

Where is the NCT07655323 trial being conducted?

This trial is being conducted at Bursa, Turkey (Türkiye).

Who is sponsoring the NCT07655323 clinical trial?

NCT07655323 is sponsored by Ferit Yetik. The principal investigator is Mürsel Ekinci, MD at Bursa City Hospital, Health Sciences University Bursa Faculty of Medicine. The trial plans to enroll 80 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology